The self-adjuvanted RNActive vaccine (CV9103) appears to be well-tolerated and immunogenic in men with advanced castration-resistant prostate cancer, according to a new phase I/IIa study.
For the first time, researchers say they have been able to use a prostate fusion biopsy to determine which tumors are the most aggressive.
It may soon be easier to link specific aberrations to response or resistance to specific treatments, making precision medicine more relevant and successful for metastatic castration resistant prostate cancer, according to a new international study published in the journal, Cell.
Clinicians soon may have a new tool for staging prostate cancer and predicting survival. Investigators at Indiana University School of Medicine are reporting in the May 14, 2015 online edition of the journal Cancer Cell, that the protein transforming growth factor beta (TGF-beta) is involved in metastatic prostate cancer.
An elevated PSA score may mean there are cancer cells, but not always. But now, a less invasive test can help more precisely determine if that biopsy is necessary.
The osteogenic protein known as runt-related transcription factor 2 (RUNX2), appears to be abnormally expressed in prostate cancer and may be associated with metastatic disease, according to researchers at the University of Michigan.
Researchers are now reporting that the loss of a key gene (WAVE1) appears to be linked to a lethal form of prostate cancer.
Researchers at the University of Central Florida say they have now come up with a $1 test using gold nanoparticles that can outperform PSA (prostate specific antigen) screening for prostate cancer.
Enzalutamide may provide a statistically significant increase in progression-free survival (PFS) compared to bicalutamide in men with nonmetastatic or metastatic castration-resistant prostate cancer.
New data are suggesting that the loss of two genes, MAP3K7 and CHD1, may be a unique driver of aggressive prostate cancer development.